440,000 Shares in ObsEva SA (OBSV) Purchased by Abingworth LLP
Abingworth LLP purchased a new stake in ObsEva SA (NASDAQ:OBSV) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 440,000 shares of the company’s stock, valued at approximately $3,480,000. ObsEva comprises 2.4% of Abingworth LLP’s investment portfolio, making the stock its 9th biggest position. Abingworth LLP owned approximately 1.48% of ObsEva at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in the company. VHCP Management II LLC boosted its position in ObsEva by 834.2% during the third quarter. VHCP Management II LLC now owns 1,401,343 shares of the company’s stock worth $11,407,000 after acquiring an additional 1,251,343 shares during the last quarter. Sphera Funds Management LTD. boosted its position in ObsEva by 12.4% during the third quarter. Sphera Funds Management LTD. now owns 260,197 shares of the company’s stock worth $2,118,000 after acquiring an additional 28,700 shares during the last quarter. Finally, Sectoral Asset Management Inc boosted its position in ObsEva by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after acquiring an additional 137,331 shares during the last quarter. Institutional investors and hedge funds own 35.91% of the company’s stock.
ObsEva SA (NASDAQ:OBSV) opened at $9.70 on Wednesday. ObsEva SA has a one year low of $5.00 and a one year high of $14.69.
A number of brokerages recently issued reports on OBSV. BMO Capital Markets began coverage on shares of ObsEva in a research report on Monday. They set an “outperform” rating and a $20.00 target price on the stock. HC Wainwright set a $25.00 target price on shares of ObsEva and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Royal Bank Of Canada restated a “buy” rating and set a $22.00 target price on shares of ObsEva in a research report on Thursday, November 2nd. Zacks Investment Research upgraded shares of ObsEva from a “sell” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Wednesday, October 18th. Finally, Credit Suisse Group began coverage on shares of ObsEva in a research note on Monday, October 9th. They set an “outperform” rating and a $16.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $19.00.
TRADEMARK VIOLATION NOTICE: “440,000 Shares in ObsEva SA (OBSV) Purchased by Abingworth LLP” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/06/440000-shares-in-obseva-sa-obsv-purchased-by-abingworth-llp.html.
ObsEva Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Want to see what other hedge funds are holding OBSV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ObsEva SA (NASDAQ:OBSV).
Receive News & Stock Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related stocks with our FREE daily email newsletter.